Ignite Creation Date:
2024-05-05 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 9:54 AM
Study NCT ID:
NCT00742690
Status:
UNKNOWN
Last Update Posted:
2014-10-15
First Post:
2008-08-26
Brief Title:
Terlipressin Given As IV Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome
Sponsor:
University of Padova
Organization:
University of Padova
Study Overview
Official Title:
Terlipressin Given As IV Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome Hrs Preliminary Results Of A Randomized Controlled Clinical Study
Status:
UNKNOWN
Status Verified Date:
2014-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It is well known that terlipressin and albumin improve renal function in patients with cirrhosis and type 1 HRS In previous studies terlipressin has been used either as intravenous boluses moving from an initial dose of 05-1 mg4 hr or as continuous intravenous infusion at the initial dose of 2 mg24 h Up to now the two schedules of iv administration of terlipressin have never been compared Nevertheless it has been hypothesized that continuous intravenous infusion assures a more steady profile of effect on portal pressure in patients with cirrhosis Thus the aim of the study will be to compare terlipressin given as iv bolus vs terlipressin given as continuous intravenous infusion in the treatment of type 1 HRS in patients with cirrhosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None